As the dust settled from Monday's grueling meeting of the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (adcom), companies, investors, analysts and, most importantly, patients and family members were left to ponder the road forward for therapies to treat Duchenne muscular dystrophy (DMD). Although the outcome of the adcom for sponsor Sarepta Therapeutics Inc. was generally deemed a step backward for its lead candidate, eteplirsen, adcom members didn't shut the door entirely in their nonbinding votes on the exon-skipping drug.